1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies




As the cancer drug market continues to face significant challenges in an environment of rising R&D costs, value-based pricing, demands for real world evidence and tougher regulation, the role of Medical Affairs teams in oncology working across the major markets of Europe – France, Germany, Italy, Spain and the UK; EU5 – becomes ever more critical.

Honing performance through smarter delivery, higher quality interaction, and effective communication with oncologists is vital for ensuring optimal performance levels of Medical Affairs teams.

In Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies, FirstWord provides robust insight on the performance and level of physician satisfaction with Medical Affairs teams representing 12 products in 4 key indications – Breast Cancer, Melanoma, Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma – across Europe’s most important markets.

Using proprietary analytics, EdgeMap and Need-Gap analysis, FirstWord offers important advanced analysis of the latest physician opinions on Medical Affairs that is both timely and critical for success in today’s oncology drugs markets.







Key Benefits

Gain insight into how EU5 oncologists and haematologist-oncologists rate Medical Affairs teams in the areas of Breast Cancer, Melanoma, NSCLC and Renal Cell Carcinoma
GUnderstand the key issues for which physicians require Medical Affairs team support
GLearn which attributes physicians value most in relation to Medical Affairs team services
GIdentify which marketed and pipeline products were rated highest across numerous measures
GContrast and compare performance of Medical Affairs teams on multiple parameters – services, brand, indication and country
GDetermine which media and frequency of interaction is perceived most positively
GBenefit from FirstWord's proprietary advanced analytics, EdgeMap and Need-Gap, to identify relative competitive positons and opportunities to develop advantage
GDetailed multi-level comparative analysis of European Medical Affairs teams versus their US counterparts

Report Features
Filled with charts and up-to-the-minute survey analysis, this report offers:

Precise and timely EdgeMap and Need-Gap analysis of oncologists' perceptions of Medical Affairs teams highlighting good and bad performance and identifying key areas for improvement
Overview of key rankings for eight marketed and four pipeline products
Examination of physicians' current touch points with Medical Affairs teams
Key findings regarding the attributes of Medical Affairs teams physicians value most and least
Comparative analysis of EU5 and US Medical Affairs teams at brand and attribute levels

Get Answers to Key Questions

How do oncologists perceive the role of Medical Affairs teams in the areas of Breast Cancer, Melanoma, NSCLC and Renal Cell Carcinoma?
How do physicians use the services of Medical Affairs teams?
What is the optimal frequency of interactions between Medical Affairs teams and physicians?
Within the competitive landscape of the EU5, what is each product’s position in terms of Medical Affairs services and support?
Which attributes of Medical Affairs teams are most likely to drive competitive advantage?
Which drugs provide the best service and claimed the highest ratings for Medical Affairs support?
What are the opportunities for corporate and brand positioning, and communication?

Key Takeaways
Medical Affairs teams, Marketing Directors and Competitive Intelligence units can use this report to:

Precisely analyse physician needs and areas of concern
Improve team responsiveness and traction with oncologists
Deliver more effective messaging and tackle areas of weakness
Provide accurate, scientifically up-to-date product information in the areas of the most need
Understand how competitors are performing, where their performance leads or lags that of your team, and how big the gaps are
Tailor interaction frequency, media and approach



What is EdgeMap Analysis?
This report includes advanced analysis of oncologists’ perceptions of Medical Affairs teams collected via an online survey. EdgeMap analysis, a proprietary analytics tool, provides an integrated, comparative analysis of the competitive set of products and attributes being evaluated in the study. It offers an overview of the market and provides a clear portrait of each product’s position within its competitive environment

What is Need-Gap Analysis?
This report includes slides that provide advanced analysis of oncologists’ perceptions of Medical Affairs teams collected via an online survey. Need-Gap analysis, a proprietary analytics tool, pinpoints areas of unmet need and provides valuable guidance on opportunities for corporate and brand positioning, and communication.


Key Fact: Interviewing Methodology
Data was collected via a 15-minute Internet-based questionnaire.


Key Fact: Sample Distribution
210 medical oncologists and haematologist-oncologists across EU5 participated in this study.

Key Fact: Screening Criteria

Have been in active practice between 5-35 years
Devote at least 50% of time to direct patient care
Have had direct interaction with a medical affairs professional in the past 6 months for at least one of the listed products


About FirstView Reports

FirstView Reports deliver two types of research and analysis: FirstView Advisory and FirstView Trends. FirstView Advisory reports are based on the qualitative insights of 10-15 leading experts, including treating and key opinion leading physicians, payers and industry stakeholders. FirstView Trends reports deliver insights based on quantitative market research which leverages FirstWord’s 1-million strong online physician community. FirstView Advisory and FirstView Trends reports deliver authoritative, actionable insight that can help industry professionals understand future pharma market dynamics and support effective decision making.

About FirstWord Reports
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors, and your markets. Covering market access, biosimilars, medical affairs, pharma sales and marketing and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


Table Of Contents

Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies
1.Current Status of Interactions with Different Medical Affairs Teams
1.1.Interactions in the past 6 months with Medical Affairs teams for each product
1.2.Physicians' current usage of services provided by Medical Affairs teams
1.3.Frequency of interactions with Medical Affairs teams for each product

2.Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes
2.1.Evaluation of overall quality of interactions with Medical Affairs teams for each product
2.2.Attribute importance of Medical Affairs teams' role to physicians' practice
2.3.EdgeMap analysis by therapy area - competitive evaluation on Medical Affairs teams performance on attributes
2.4.Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
2.5.Need-Gap analysis by product

3.Preferred Interaction Media, Frequency and Suggestions for Improvement
3.1.Preferred interaction media and frequency
3.2.Suggestions for improvement

4.Appendix
4.1.Physician profile
4.2.Detailed satisfaction scores

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Lung Cancer: Analytical Tool

August 2016 $ 8096

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.